We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Drugs Less Effective Than Lifestyle Modifications in Increasing HDL

By Biotechdaily staff writers
Posted on 05 Sep 2007
A recently published review article suggested that lifestyle modifications were more successful in raising high-density lipoprotein (HDL) levels than most available drug treatments.

Nearly 40% of all heart attacks and related cardiovascular problems occur in individuals with low HDL levels. More...
Those with blood levels of HDL lower than 35 mg/dl (16-18% of men and 3- 6% of women) have eight times the risk of heart disease compared to those with 65 mg/dl or more. Thus, finding drug treatments to raise the level of HDL has become of major interest.

A team of investigators reviewed the literature related to attempts to raise HDL levels and compared results from lifestyle modification (dieting, exercise, etc.) to those from various drug treatments. Results of the review of 31 randomized controlled trials published in the August 15, 2007, issue of the Journal of the American Medical Association revealed that several lifestyle modifications were effective in increasing HDL. Among these lifestyle modifications were weight loss, exercise, smoking cessation, moderate alcohol consumption, and eating fish or taking fish oil to increase intake of omega-3 fatty acids.

As for pharmacologic approaches, the study found that the most effective currently available drug to raise HDL is the vitamin niacin, taken in high doses. "Statins, niacin, and fibrates are available pharmacological agents that increase HDL; however, they may be associated with adverse side effects,” said contributing author Dr. Mehdi Shishehbor from the Cleveland Clinic (OH, USA).

"Despite the recent negative HDL trials, this field is extremely exciting and the pace of discovery is unbelievably fast,” Dr. Shishehbor said. "At least one other drug with a novel mechanism of action is also in trials--and at least three other approaches have led to new drugs in the pipeline.”


Related Links:
Cleveland Clinic

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.